Meglumine acridonacetate in combined antiviral treatment of HBeAg-positive chronic hepatitis B

• Published in: Georgian medical news no. 219; p. 33
• Main Authors: Stel'makh, V V, Okovityĭ, S V, Romantsov, M G, Tuan, N Kh, Oiungerel, M
• Format: Journal Article
• Language: Russian
• Published: Georgia (Republic) 01.06.2013
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents - therapeutic use; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens - immunology; Hepatitis B virus - immunology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Humans; Interferon-alpha - therapeutic use; Male; Meglumine - therapeutic use; Middle Aged; Treatment Outcome; Young Adult

647 patients with HBeAg positive chronic hepatitis B who have not previously received antiviral therapy were participated in randomized, post-marketing, double-blinded, placebo-controlled clinical trial. Interferon inducer cycloferon was presented as study drug. 323 patients with chronic hepatitis B...